https://mdm.mi.uni-heidelberg.de/954?lang=it&form-lang=en
Breast Cancer NCT00310180 Follow-Up - TAILORx Second Primary Form - 3236572v1.0 - Portale di...
TAILORx Second Primary Form Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast...
https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy
TAILORx finds no chemotherapy benefit for most early breast cancers - NCI
Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual...
chemotherapy benefitbreast cancersfinds
https://www.prnewswire.com/news-releases/new-tailorx-data-published-today-in-jama-oncology-add-to-strong-evidence-base-reinforcing-unique-ability-of-oncotype-dx-breast-recurrence-score-test-to-guide-chemotherapy-treatment-300927321.html
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique...
/PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment...
https://mdm.mi.uni-heidelberg.de/954?lang=pt
Breast Cancer NCT00310180 Follow-Up - TAILORx Second Primary Form - 3236572v1.0 - Portal para...
TAILORx Second Primary Form Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast...